Global Leading Market Research Publisher QYResearch announces the release of its latest report “Medicinal Stevioside – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Medicinal Stevioside market, including market size, share, demand, industry development status, and forecasts for the next few years.
Addressing core industry needs: Diabetes, obesity, and hypertension patients require sugar alternatives with therapeutic benefits – but artificial sweeteners have safety concerns, while natural sugars add calories. Medicinal stevioside solves this as a natural, non-caloric high-intensity sweetener (200–300x sucrose) with demonstrated pharmacological activities including glucose regulation, antihypertensive effects, and anti-inflammatory properties. Key drivers include clean-label trends, metabolic disease prevalence, and functional food demand.
The global market for Medicinal Stevioside was estimated to be worth US$ 95 million in 2025 and is projected to reach US$ 143 million, growing at a CAGR of 6.1% from 2026 to 2032. In 2024, global sales reached approximately 2,140 tons, with an average price of US$ 41,500 per ton.
Medicinal stevioside refers to a group of natural high-intensity sweeteners extracted from the leaves of Stevia rebaudiana Bertoni, primarily composed of diterpene glycosides such as stevioside and rebaudiosides. Beyond its wide application as a non-caloric sweetener in the food industry, medicinal stevioside has demonstrated various pharmacological activities, including glucose regulation, antihypertensive effects, anti-inflammatory, and antioxidant properties. These characteristics suggest its potential therapeutic applications in managing conditions such as diabetes, obesity, and cardiovascular disorders.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098444/medicinal-stevioside
Market Segmentation & Key Players
The Medicinal Stevioside market is segmented as below:
Leading Suppliers: PureCircle, Cargill, Sunrise Nutrachem Group, Crodarom, Merisant, Shandong Huaxian Haosen Biotechnology, Shandong Sugar Baby Biotechnolog, Jilin Aodong Biotechnology, Shandong Jiake Biotechnology, Shandong Haigen Biotechnology, Hunan Erkang Pharmaceutical, Sichuan Bolley Heng Pharmaceutical, BONTAC Biotechnology.
Segment by Type: Purity 95%–98% | Purity 98%–99% | Purity Above 99%
Segment by Application: Pharmaceuticals | Health Supplements | Others
Exclusive Industry Insights
Discrete plant extraction & purification: Medicinal stevioside is manufactured via water extraction of Stevia leaves, followed by multi-step purification (membrane filtration, crystallization, chromatography). Higher purity requires additional processing steps (re-crystallization, HPLC polishing), increasing cost exponentially.
Technical differentiation – purity grades:
- Purity 95%–98% (28% revenue): Technical grade for food/beverage applications. Lower cost, contains mixed glycosides (stevioside + rebaudioside A).
- Purity 98%–99% (48% revenue): Pharmaceutical grade. Reduced off-taste (bitter/metallic notes). Largest segment for supplements and pharma excipients.
- Purity Above 99% (24% revenue): High-purity rebaudioside A or stevioside isolates. For research, clinical studies, and premium formulations. Fastest-growing (CAGR 7.2%).
Recent 6-month data (Oct 2025 – Mar 2026):
- Health supplements largest application (52% revenue), driven by sugar-free and keto products.
- Pharmaceuticals fastest-growing (CAGR 6.8%), with clinical trials for diabetes and hypertension.
- Average price increased 5% due to Stevia leaf supply constraints.
User case – Nutraceutical manufacturer (US, stevia-based supplements): Launching stevioside capsules (250mg, 98% purity) for blood sugar support achieved US$ 15M revenue in first year. Key claim: “supports healthy glucose metabolism.” Repeat purchase rate: 34% (vs. industry avg 22%).
Pharmacological evidence (clinical studies):
| Condition | Mechanism | Evidence Level |
|---|---|---|
| Diabetes | Increases insulin secretion, improves insulin sensitivity | Moderate (RCTs, n=500+) |
| Hypertension | Vasodilation, calcium channel blockade | Moderate |
| Obesity | Reduces caloric intake, impacts appetite | Preliminary |
| Inflammation | NF-κB pathway inhibition | Preclinical |
Application insights: Health Supplements (52%) – capsules, powders, gummies for blood sugar support, weight management. Pharmaceuticals (35%) – API for anti-diabetic formulations, excipient in oral liquids. Others (13%) – functional foods, medical nutrition, research reagents.
Regulatory status:
- FDA: GRAS for food; no approved therapeutic claims (sold as dietary supplement).
- EMA: Novel food approval; pharmaceutical use under investigation.
- China (NMPA): Listed as food additive and API for traditional medicine.
Regional snapshot: Asia-Pacific leads with 55% revenue share (China 40%, Stevia cultivation + processing). North America holds 25% (supplement demand). South America 12% (Paraguay/Brazil origin). Europe 8%.
Conclusion
The medicinal stevioside market is growing rapidly, driven by metabolic disease prevalence, clean-label demand, and functional health trends. Success depends on purity control, taste improvement (rebaudioside M/A), and clinical evidence generation. The projected US$ 143 million market by 2032 appears achievable.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
